Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel
Categories (click each to see list of all clinical trials associated with that category): Cellular Therapy Support Service - CAR-T (ONC), Lymphoma/CLL (ONC)
Current Status: Open
Phase: N/A (Cancer Control)
Principal Investigator: Lunning, Matthew
Contact Information:
Sarah Snook
sarah.snook@unmc.edu
Eligibility: https://clinicaltrials.gov/ct2/show/NCT05776160?term=NCT05776160&draw=2&rank=1#eligibility
Summary
The objective of this study is to provide access to axicabtagene ciloleucel that is OOS for commercial release to subjects with an approved labeled indication.
The outcome measure is:
- Incidence of SAEs and deaths from informed consent to 30 days post infusion or early withdrawal.